From: The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
Included studies
Cases
Chi
I2 %
SMD
95 % CI
P
MOF
1 [32]
44
–
−0.49
−1.09,0.11
0.11
Length of ICU stay
6 [31, 33, 35, 37, 39, 43]
591
34.92
86 %
−0.52
−1.06,0.01
0.06
Mechanical ventilation days
6 [31, 33, 35, 37–39]
570
32.24
84 %
−0.37
−0.90, 0.17
0.17
